5-羟基-2-吡嗪羧酸乙酯 | 54013-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-羟基-2-吡嗪羧酸乙酯
• 英文名称: 2-carbethoxy-5-hydroxypyrazine
• 英文别名: 5-oxo-4,5-dihydro-pyrazine-2-carboxylic acid ethyl ester；2-Carbethoxy-5-hydroxypyrazin；Ethyl 5-hydroxypyrazine-2-carboxylate；ethyl 6-oxo-1H-pyrazine-3-carboxylate
• CAS: 54013-03-5
• 化学式: C₇H₈N₂O₃
• mdl: MFCD18070853
• 分子量: 168.152
• InChiKey: NXLBHIWYUOPXIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  环丁基甲醇 、 5-羟基-2-吡嗪羧酸乙酯 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以62%的产率得到ethyl 5-(cyclobutylmethoxy)-pyrazine-2-carboxylate
  参考文献：
  名称：

  [EN] PYRAZINE DERIVATIVES
  [FR] DÉRIVÉS DE PYRAZINE

  摘要：

  本发明涉及式(I)的化合物，其中R1R2为氢、较低的烷基、较低的烷氧基、受卤素取代的较低烷基、受卤素取代的较低烷氧基、环烷基、OCH2-环烷基或杂环烷基，该杂环烷基可以选择性地受卤素取代，但R1和R2中的一个为氢，或者R1和R2与它们连接的碳原子一起形成苯环，该苯环可以选择性地受较低烷基取代；R3/R4为氢、卤素或氰基；但R3和R4中的一个为氢；或其药学上适宜的酸盐，所有的外消旋混合物，它们对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、躁郁症、注意缺陷多动障碍（ADHD）、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。

  公开号：

  WO2014072257A1

文献信息

• [EN] NEW BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010028981A1

  公开（公告）日：2010-03-18

  The invention is concerned with novel benzimidazole derivatives of Formula (I) wherein A, n and R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds act on Farnesyl X receptor (FXR) and against cholesterol and lipid illnesses, diabetes, obesity, psoriasis, cancer, osteoporosis, Parkinson's and Alzheimer's disease.

  这项发明涉及一种新型苯并咪唑衍生物，其化学式为（I），其中A、n以及R1至R7如描述和索赔中所定义，以及其生理上可接受的盐和酯。这些化合物对法尼酰X受体（FXR）起作用，对抗胆固醇和脂质疾病、糖尿病、肥胖症、牛皮癣、癌症、骨质疏松症、帕金森病和阿尔茨海默病具有作用。
• NEW BENZIMIDAZOLE DERIVATIVES
  申请人：Benson Gregory Martin

  公开号：US20100063101A1

  公开（公告）日：2010-03-11

  The invention is concerned with novel benzimidazole derivatives of formula (I) wherein A, n and R 1 to R 7 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.

  该发明涉及式（I）中的新型苯并咪唑衍生物，其中A，n和R1到R7如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物可用作药物。
• PYRAZINE DERIVATIVES
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20160272626A1

  公开（公告）日：2016-09-22

  The present invention relates to compounds of formula wherein R 1 /R 2 are hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, OCH 2 -cycloalkyl or heterocycloalkyl which is optionally substituted by halogen, with the proviso that one of R 1 and R 2 is hydrogen, or R 1 and R 2 form together with the carbon atom to which they are attach a phenyl ring, which may be optionally substituted by lower alkyl; R 3 /R 4 are hydrogen, halogen or cyano; with the proviso that one of R 3 and R 4 is hydrogen; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式为的化合物，其中R1 / R2为氢，较低的烷基，较低的烷氧基，由卤素取代的较低烷基，由卤素取代的较低烷氧基，环烷基，OCH2-环烷基或杂环烷基，该杂环烷基可选择性地被卤素取代，但其中之一为氢，或R1和R2与它们附着的碳原子形成苯环，该苯环可以选择性地被较低的烷基取代; R3 / R4为氢，卤素或氰基;但其中之一为氢;或其药学上适用的酸加成盐，所有外消旋混合物，所有其对应的对映体和/或光学异构体，可用于治疗抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍（ADHD），与压力相关的障碍，精神障碍，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，高血压，物质滥用，代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍，睡眠和昼夜节律障碍以及心血管疾病。
• US8088930B2
  申请人：——

  公开号：US8088930B2

  公开（公告）日：2012-01-03
• [EN] PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014072257A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds of formula (I), wherein R1R2 are hydrogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, cycloalkyl, OCH2-cycloalkyl or heterocycloalkyl which is optionally substituted by halogen, with the proviso that one of R1 and R2 is hydrogen, or R1 and R2 form together with the carbon atom to which they are attach a phenyl ring, which may be optionally substituted by lower alkyl; R3/R4 are hydrogen, halogen or cyano; with the proviso that one of R3 and R4 is hydrogen; or to a pharmaceutically suitable acid addition salt thereof, to all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式(I)的化合物，其中R1R2为氢、较低的烷基、较低的烷氧基、受卤素取代的较低烷基、受卤素取代的较低烷氧基、环烷基、OCH2-环烷基或杂环烷基，该杂环烷基可以选择性地受卤素取代，但R1和R2中的一个为氢，或者R1和R2与它们连接的碳原子一起形成苯环，该苯环可以选择性地受较低烷基取代；R3/R4为氢、卤素或氰基；但R3和R4中的一个为氢；或其药学上适宜的酸盐，所有的外消旋混合物，它们对应的对映体和/或光学异构体，可用于治疗抑郁症、焦虑症、躁郁症、注意缺陷多动障碍（ADHD）、与压力有关的疾病、精神疾病、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、高血压、物质滥用、代谢紊乱、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。